Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Mustafa S, VandenBussche CJ, Ali SZ, Siddiqui MT, Wakely PE. Cytomorphologic findings of low-grade fibromyxoid sarcoma. J Am Soc Cytopathol. 2020;9(3):191-201.

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653-1668.

Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020;22:34-44.

Westblade LF, Errington J, Dörr T. Antibiotic tolerance. PLoS Pathog. 2020;16(10):e1008892.

Jenkins S, Ledeboer NA, Westblade LF, Burnham CA, Faron ML, Bergman Y, et al. Evaluation of NG-Test Carba 5 for Rapid Phenotypic Detection and Differentiation of Five Common Carbapenemase Families: Results of a Multicenter Clinical Evaluation. J Clin Microbiol. 2020;58(7).

Mostyka M, Jessurun J, Matrai C. Sarcoid-Like Granulomatosis in a Patient With Breast Cancer Mimicking Refractory Metastatic Disease. Int J Surg Pathol. 2020;28(6):668-671.

Chung EY, McIlroy K, Fung C, Seshan SV, Moran S, Coleman PL. Glomerular, Mesangial, and Tubular Cytoplasmic Fibrillary Inclusions in a Patient with Light-Chain Proximal Tubulopathy. Nephron. 2020;144(4):190-194.

G Park K, Lee JH, Soriano E, Choi M, Bao K, Katagiri W, et al. Rapid and Selective Targeting of Heterogeneous Pancreatic Neuroendocrine Tumors. iScience. 2020;23(4):101006.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell Rep. 2020;30(3):755-770.e6.

Hwang I, Pan H, Yao J, Elemento O, Zheng H, Paik J. CIC is a critical regulator of neuronal differentiation. JCI Insight. 2020;5(9).